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Abstract
When variables that are treatment effect modifiers also influence the decision to par-
ticipate in a clinical trial, the average effect among trial participants will differ from
the effect in other populations of trial-eligible individuals. In this tutorial, we con-
sider methods for transporting inferences about a time-fixed treatment from trial par-
ticipants to a new target population of trial-eligible individuals, using data from a
completed randomized trial along with baseline covariate data from a sample of non-
participants. We examine methods based on modeling the expectation of the outcome,
the probability of participation, or both (doubly robust). We compare the finite-sample
performance of different methods in a simulation study and provide example code to
implement the methods in software. We illustrate the application of the methods
to the Coronary Artery Surgery Study, a randomized trial nested within a cohort of
trial-eligible patients to compare coronary artery surgery plus medical therapy versus
medical therapy alone for patients with chronic coronary artery disease. Lastly, we
discuss issues that arise when using the methods in applied transportability analyses.
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Participants in randomized controlled trials often differ from trial-eligible individuals seen
in clinical practice with respect to the distribution of covariates that modify the treatment
effect. Because of such differences, the average treatment effect in the population of trial
participants differs from the average treatment effect in other populations of trial-eligible in-
dividuals [1]. This lack of transportability of trial results has been documented by numerous
surveys comparing the distribution of baseline covariates between clinical trial participants
and samples of patients seen in clinical practice (e.g., [2–4]).
In medicine, the task of assessing whether trial findings are relevant to a new target
population is often handled via informal transportability assessments [5]. Clinicians and
policy makers, however, cannot easily use such assessments to transport inferences from a
clinical trial to the specific target population they are interested in (e.g., the population of
patients in their practice or the population in which the policy will be applied). Furthermore,
it is unclear how they can assess the reliability and performance of informal assessments for
guiding medical or policy decisions.
In this tutorial, we show that instead of relying exclusively on informal assessments, we
can use formal statistical methods for transporting inferences about the average effect of a
time-fixed (i.e., non-time-varying) treatment from trial participants to new target popula-
tions [6–15]. We focus on a special but common case of the transportability problem: when
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data on the treatment, outcome, and baseline covariates are available from a completed
randomized trial, but only data on baseline covariates are available from a sample of trial-
eligible non-participants from the target population. We examine methods for transporting
inferences from trial participants to the target population using models for the expectation
of the outcome, the probability of trial participation, or both (doubly robust). We assess the
finite-sample performance of the methods in simulation studies and provide example code
to implement the methods in R. We apply the methods to a randomized trial nested within
a cohort of eligible patients that compared coronary artery surgery plus medical therapy
versus medical therapy alone, for patients with chronic coronary artery disease. Lastly, we
discuss issues that arise when using the methods in applied transportability analyses.
1 Study designs for transporting trial findings
The most natural study design for transporting inferences from trial participants to a new
target population, is a trial nested within a cohort of eligible individuals, including those who
refuse to participate in the randomized component of the study. In this design, investigators
collect baseline covariate information from all cohort members, but often collect treatment
and outcome information only from randomized individuals. For example, this setup occurs
in comprehensive cohort studies [16] and in trials embedded in health-care systems where
data are routinely collected from all members of the system [17].
Another design for transporting inferences to a new target population uses an artificial
composite dataset created by appending the data from a completed trial to a separately
obtained sample from the target population [6]. As in the trial-nested-within-cohort design,
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baseline covariate information is available from all patients, but treatment and outcome in-
formation is only available from randomized participants (e.g., when the interventions exam-
ined in the trial are not commercially available and no observational data can be collected).
This setup arises often in drug development and regulatory settings, because exposure and
outcome data are available only from a small number of clinical trial participants prior to
drug approval, but baseline covariate data can be collected from large samples of untreated
individuals who would be eligible for participation in the trials. The setup also arises in
public policy research, when randomized trials are conducted in selected samples but target
population data are available from administrative databases or surveys.
The methods we describe in this tutorial can be used both in trials nested within cohorts
of eligible individuals and composite datasets.
2 Causal contrasts
The data generated from the designs described in the previous section consist of independent
observations, indexed by i = 1, . . . , n, on baseline covariates X; treatment A; outcome Y ;
and a trial participation indicator S that takes the value 1 for trial participants or 0 for
non-participants. The data exhibit a special missingness pattern: for trial participants we
have data on (S,X,A, Y ), but for non-participants we only have data on (S,X). Table 1
shows the observed data structure for the special case of binary treatment.
We use the random variables Y a to denote the potential (counterfactual) outcome under
intervention to set treatment to a, possibly contrary to fact [18,19]. We only consider discrete
treatments in this tutorial; extensions to continuous treatments are straightforward. For any
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two treatments, a 6= a′, a causal effect of interest is the average treatment effect in the target
population of eligible non-participants,
δ = E[Y a − Y a′ |S = 0].
The average treatment effect among non-participants is not equal to the average treatment
effect among trial participants, E[Y a − Y a′|S = 0] 6= E[Y a − Y a′ |S = 1], when the effect
of treatment varies over baseline covariates that are differentially distributed between trial
participants and non-participants [20,21].
When using the trials-nested-in-cohorts design, another causal effect, the average effect
in the population of all eligible individuals, E[Y a−Y a′ ], may also be of interest, and we have
discussed its identification and estimation in previous work [22]. Even if the primary target
of inference for the trial-nested-in-cohort design is E[Y a − Y a′ ], investigators are typically
also interested in efficiently estimating the effect among non-participants, E[Y a − Y a′ |S =
0]. Comparing the effect among eligible non-participants against the effect among trial
participants is often of substantial scientific and policy interest. Importantly, when using the
composite dataset design, E[Y a − Y a′ ] is not a meaningful estimand because the population
implied by the composite dataset design is a mixture of the population of trial participants
and the target population, with arbitrary mixing proportions (determined by the sample size
of the trial and target sample). Thus, for composite datasets, E[Y a−Y a′ |S = 0] is the more
reasonable target of inference.
In the remainder of this tutorial we focus on the identification and estimation of the
components of the average treatment effect among eligible non-participants, E[Y a|S = 0],
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under either of the designs discussed in Section 1.
3 Identifiability conditions & identification
3.1 Identifiability conditions
We now discuss sufficient conditions for identifying the mean of the potential outcomes under
each treatment a in in the population of trial-eligible non-participants, E[Y a|S = 0].
(1) Consistency of potential outcomes: The observed outcome for the ith individual
who received treatment a equals that individual’s potential outcome under the same treat-
ment, that is, if Ai = a, then Yi = Y
a
i .
(2) Mean exchangeability (over A): Among trial participants, the potential outcome
mean under treatment a is independent of treatment, conditional on baseline covariates,
E[Y a|X,A = a, S = 1] = E[Y a|X,S = 1].
We expect conditional exchangeability in the trial to hold, regardless of whether the random-
ization was unconditional or conditional on covariates. The mean exchangeability assumption
is weaker than the assumption of exchangeability in distribution, Y a ⊥ A|X,S = 1.
(3) Positivity of treatment assignment: In the trial, the probability of being assigned
to each of the treatments being compared, conditional on the covariates needed for exchange-
ability, is bounded away from zero: 0 < Pr[A = a|X,S = 1] for each a.
(4) Mean transportability (exchangeability over S): The potential outcome mean is
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independent of trial participation, conditional on baseline covariates:
E[Y a|X,S = 1] = E[Y a|X].
Again, this assumption is weaker than the often-invoked assumption of conditional trans-
portability in distribution, Y a ⊥ S|X.
(5) Positivity of trial participation: The probability of participating in the trial, condi-
tional on the covariates needed to ensure mean transportability, is positive,
Pr[S = 1|X = x] > 0, for every x such that fX(x) > 0.
Consistency, mean exchangeability, and positivity of treatment assignment are expected
to hold in (marginally or conditionally) randomized clinical trials of well-defined interven-
tions. In contrast, mean transportability and positivity of trial participation are strong and
largely untestable assumptions, and their plausibility needs to be assessed on the basis of
substantive knowledge when transporting inferences from a trial to a new target population.
3.2 Identification
Under the above assumptions, as shown in the Appendix, for each treatment a, the poten-
tial outcome mean in the target population of non-participants can be identified using the
observed data,
E[Y a|S = 0] = E[E[Y |X,A = a, S = 1]|S = 0].
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These potential outcome means are inherently interesting. Furthermore, the treatment effect
among trial-eligible non-participants can be identified as
E[Y a − Y a′|S = 0] = E[E[Y |X,A = a, S = 1]|S = 0]− E[E[Y |X,A = a′, S = 1]|S = 0].
In the next section we review methods for estimating E[Y a|S = 0].
4 Estimating potential outcome means in the target
population
We consider three approaches for estimating the potential outcome mean in the target popu-
lation of non-participants: (1) outcome modeling followed by standardization; (2) probability
of trial participation modeling followed by inverse odds weighting; and (3) doubly robust
approaches that combine outcome and trial participation modeling. Under the consistency
assumption, these methods can be thought of as solutions to a missing data problem for
the outcome, where the missing data indicator is the product S × I(A = a), and I(·) is the
indicator function. In the Appendix, we show that the three approaches provide consistent
estimators (i.e., converge in probability) for E[Y a|S = 0] provided the identifiability condi-
tions hold and models are correctly specified; here, we focus on developing intuition about
the methods. Throughout, we assume that the models for the probability of participation
and the expectation of the outcome are parametric (finite-dimensional), as is usually the
case in applied work (we address more flexible models in the Discussion section).
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4.1 Outcome modeling followed by standardization
The first approach transports inferences from trial participants to the population of non-
participants by “extrapolating” an outcome regression model fit among the former to a
sample of the latter [23]. In essence, we use data from trial participants to estimate models
for the expectation of the outcome and then standardize the model predictions to the baseline
covariate distribution of the non-participants. The estimator for the potential outcome mean
among eligible non-participants under treatment a is
µ̂OM(a) =
{ n∑
i=1
(1− Si)
}−1 n∑
i=1
(1− Si)ga(Xi; β̂), (1)
where ga(Xi; β̂) is a predicted value from a model (with finite-dimensional parameter β) for
E[Y |X,A = a, S = 1]. We usually estimate separate outcome models in each treatment
group of the trial, to allow for all possible treatment × covariate interactions. When the
identifiability conditions hold and the model is correctly specified the estimator is consistent
for the potential outcome mean among eligible non-participants.
4.2 Trial participation modeling and odds weighting
The second approach transports inferences from trial participants to the population of non-
participants using a model for the probability of trial participation [6, 15]. In essence, we
are treating the randomized trial participants as a sample from the target population with
sampling probabilities that depend on baseline covariates and need to be estimated, an idea
that connects this approach to survey sampling [24]. Specifically, we estimate the potential
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outcome mean under treatment a among trial non-participants as
µ̂IOW1(a) =
{ n∑
i=1
(1− Si)
}−1 n∑
i=1
ŵiSiI(Ai = a)Yi, (2)
with ŵi defined as
ŵi =

1− h(Xi; γ̂)
h(Xi; γ̂)ea(Xi; θ̂)
, if Si = 1 and Ai = a;
0 , otherwise.
Here, h(Xi; γ̂) is a predicted value from a model (with finite-dimensional parameter γ) for
the probability of participation in the trial Pr[S = 1|X], and ea(X; θ̂) is a predicted value
from a model (with finite-dimensional parameter θ) for the probability of being assigned to
treatment a among trial participants Pr[A = a|X,S = 1]. The probability of participation
in the trial is, in general, unknown and has to be estimated (e.g., by fitting a logistic re-
gression model). In contrast, the probability of treatment in the randomized trial is known
(determined by the investigators) and the true values can be used instead of estimated values
(estimating the probability may, however, lead to smaller standard errors). We refer to the
estimator in (2) as an “odds of participation weighted” estimator and the weights as “odds
of participation” weights because
1− h(Xi; γ̂)
h(Xi; γ̂)
is the inverse of the estimated odds of trial
participation conditional on baseline covariates.
An alternative odds of participation weighted estimator normalizes the weights to sum
to 1,
µ̂IOW2(a) =
{ n∑
i=1
ŵiSiI(Ai = a)
}−1 n∑
i=1
ŵiSiI(Ai = a)Yi. (3)
11
In survey research, this estimator is referred to as the ratio estimator [25]; it can be obtained
as the solution of the estimating equations of weighted least squares regression of the outcome
on treatment, using weights equal to ŵi for trial participants and 0 for non-participants.
When the identifiability conditions hold and the model for the probability of participation
is correctly specified both odds weighting estimators are consistent for the potential outcome
mean among eligible non-participants. The small difference in the normalization of the
weights between IOW1 and IOW2 can have a big effect when weights are highly variable [26],
because estimator (2) is unbounded (i.e., it may produce estimates that fall outside the
support of the outcome variable), whereas estimator (3) is bounded by the range of the
observed outcome.
4.3 Doubly robust estimators
In practical applications, background knowledge is typically inadequate to ensure correct
specification of the working models for the probability of participation or the expectation
of the outcome, and misspecification of these models can lead to estimator inconsistency.
We can gain some robustness to misspecification and increase efficiency by combining the
two models to obtain doubly robust estimators that are consistent when either model is
correctly specified [27–29]. Here, we examine three doubly robust estimators that are easy
to implement in standard statistical software.
In-sample one-step doubly robust estimator: The first doubly robust estimator we
consider relies on estimating models for the conditional expectation of the outcome, ga(Xi; β);
the probability of trial participation, h(Xi; γ); and (optionally) the probability of treatment
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among trial participants, ea(Xi; θ). Predicted values from these models are then combined
to obtain the unbounded estimator
µ̂DR1(a) =
{ n∑
i=1
(1−Si)
}−1 n∑
i=1
{
ŵiSiI(Ai = a)
{
Yi−ga(Xi; β̂)
}
+(1−Si)ga(Xi; β̂)
}
, (4)
where ŵi was defined in the previous section.
In-sample one-step doubly robust estimator with normalized weights: Using the
same strategy of normalizing the weights as for IOW2, an alternative, bounded (provided
the outcome model is well-chosen) variant of DR1 is
µ̂DR2(a) =
{ n∑
i=1
ŵiSiI(Ai = a)
}−1 n∑
i=1
ŵiSiI(Ai = a)
{
Yi − ga(Xi; β̂)
}
+
{ n∑
i=1
(1− Si)
}−1 n∑
i=1
(1− Si)ga(Xi; β̂).
(5)
Weighted regression doubly robust estimator: A third doubly robust estimator in-
volves fitting a model for the outcome conditional on covariates among trial participants,
using a weighted regression with the weights ŵi as defined above, and then standardizing
the predicted values, ga(Xi; β̂
∗),to the covariate distribution of eligible non-participants,
µ̂DR3(a) =
{ n∑
i=1
(1− Si)
}−1 n∑
i=1
(1− Si)ga(Xi; β̂∗), (6)
where β̂∗ is the vector of estimated parameters from the weighted outcome regression. This
estimator is bounded provided the outcome model is well-chosen and doubly robust when the
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outcome is modeled with a linear exponential family quasi-likelihood [30] and the canonical
link function [26,31].
Provided the identification conditions hold, doubly robust estimators are consistent and
asymptotically normal when either the model for the probability of participation or the
expectation of the outcome is correctly specified [32]. When both models are correctly
specified the large-sample variance of the doubly robust estimators is less than or equal the
variance of the inverse odds weighting estimators [28, 32]. When one of the two models is
incorrectly specified, the asymptotic distribution of the doubly robust estimators remains
normal (and centered on the true value) but their variance is increased. In rare cases, when
misspecification of the outcome model is combined with highly variable weights, doubly
robust estimators can perform worse than non-doubly robust estimators that use the same
misspecified outcome model [26,33].
4.4 Inference
When using parametric working models, all the estimators described above can be viewed
as partial M-estimators [34] and it is possible to employ the usual “sandwich” approach
to obtain their sampling variances (e.g., [35, 36]). Inference based on the non-parametric
bootstrap [37], however, is easy to obtain with modern software and will often be preferred
in practice.
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5 Simulation study
We conducted a simulation study to examine the finite-sample performance of different esti-
mators for the average treatment effect in the target population of eligible non-randomized
patients.
5.1 Data generation
We run a factorial experiment using 3 trial sample sizes (nRCT) × 3 target population sample
sizes (nobs) × 2 magnitudes of departure from additive effects in the outcome model (φ) × 2
magnitudes of selection (µ), resulting in a total of 36 simulation scenarios.
We considered nRCT of 250, 500, or 1000 randomized participants and nobs of 2,500, 5,000
or 10,000 non-randomized individuals. We generated baseline covariates for randomized
trial participants (S = 1), as X1i ∼ N (µ, 1) and Xji ∼ N (1, 1); j = 2, 3; i = 1, ..., nRCT.
We then generated baseline covariates for the sample of eligible non-participants (S = 0),
with Xji ∼ N (0, 1); j = 1, 2, 3; i = nRCT + 1, ..., n = nRCT + nobs. The difference in the
means of the covariate distributions of trial participants and non-participants represents
selection into the trial based on baseline covariates. The parameter µ controls selection on
X1; we used values 0 and 1, representing no and strong selection. Because the distribution of
baseline covariates is homoskedastic over S, a logistic regression model of S on (X1, . . . , X3)
is correctly specified [38]. We generated outcomes using the linear model
Yi = τAi + φX1iAi + ψXi + i,
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where τ is the main treatment effect, φ determines the magnitude of effect modification
by X1; Xi = (X1i, X2i, X3i)
′, ψ = (1, 1, 1), and i ∼ N (0, 1). We examined scenarios with
different levels of effect modification by setting φ to 0 or 1; we set the “main” treatment
effect to τ = 1 in all scenarios.
For each simulated dataset, we applied the estimators in equations (1) through (6), and
also obtained a trial-only estimator of the treatment effect. All working models required
for the different estimators were correctly specified, in the sense that the true models were
nested within the parametric working models on which the estimators relied. Specifically,
outcome models included main effects for all covariates and were fit separately in each arm;
logistic regression models for trial participation and treatment included the main effects of
all covariates; all models had intercept terms. We estimated the bias and variance for each
estimator over 10,000 runs for each scenario.
5.2 Simulation results
Tables 2 and 3 summarize simulation results from selected simulation scenarios for con-
tinuous, normally distributed outcomes and linear outcome models. Additional simulation
results are presented in Appendix Tables A1 and A2.
When all models were correctly specified, all estimators were approximately unbiased,
even with fairly small trial and target population sample sizes. The outcome-model based
estimator had the lowest variance, followed closely by the three doubly robust estimators.
The probability of participation-based estimators had substantially larger variance than all
other estimators; that variance, though, became smaller with increasing trial sample sizes.
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When trial sample size was much smaller than the target sample size, in the presence of
strong selection on covariates, estimators that used weights normalized to sum to one (IOW2
and DR2 and DR3) had smaller variance compared to estimators that used unnormalized
weights (IOW1 and DR1). As expected, in the presence of effect modification, the trial-only
estimator gave different results compared to the estimators in equations (1) through (6).
The trial-only estimator is biased for E[Y 1−Y 0|S = 0] when selection into the trial depends
on the effect modifier, but is, of course, unbiased for E[Y 1 − Y 0|S = 1] under very general
conditions.
5.3 Code to implement the methods
In the Appendix, we provide R [39] code implementing the methods compared in the sim-
ulation study. Specifically, we provide a collection of basic stand-alone functions, one for
each estimator in equations (1) through (6), using parametric working models estimated by
standard maximum likelihood methods. Readers can modify the functions to incorporate al-
ternative estimation approaches and to obtain bootstrap-based inference. To allow inference
with standard errors obtained with the sandwich method, we also provide an implementation
of the estimators using the R package geex [40]. Lastly, we provide Stata code to reproduce
the simulation study.
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6 Transportability analyses for the Coronary Artery
Surgery Study
The Coronary Artery Surgery Study (CASS) included a randomized trial nested within a co-
hort study, comparing coronary artery surgery plus medical therapy (henceforth, “surgery”)
versus medical therapy alone for patients with chronic coronary artery disease. Of the 2099
eligible patients, 780 consented to randomization and 1319 declined. We excluded six pa-
tients for consistency with prior CASS analyses [41, 42] and in accordance with CASS data
release notes; in total, we used data from a total of 2093 patients. Details about the design
of the CASS are available elsewhere [43,44]. Here, we focus on estimating the survival prob-
ability and treatment effects among eligible non-participants and comparing them against
estimates obtained among trial participants.
We implemented the methods described in Section 4 to estimate the 10-year risk (cu-
mulative incidence proportion) of death from any cause in the surgery and medical therapy
groups, the risk difference, and the relative risk for the population of eligible patients who
did not consent to randomization. Risks are reasonable measures of incidence in CASS be-
cause no patients were censored during the first 10 years of follow-up. The working models
for the outcome, the probability of participation in the trial, and the probability of treat-
ment were logistic regression models with the following covariates: age, severity of angina,
history of previous myocardial infarction, percent obstruction of the proximal left anterior
descending artery, left ventricular wall motion score, number of diseased vessels, and ejection
fraction. We selected variables for inclusion in the models based on a previous analysis of
the CASS data [42]; age and ejection fraction were modeled using restricted cubic splines
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with 5 knots [45]. We used bootstrap re-sampling (10,000 samples of as many observations
as in the dataset) to obtain percentile 95% confidence intervals.
Of the 2093 patients in the CASS dataset, 1686 had complete data on all baseline covari-
ates (731 randomized, 368 to surgery and 363 to medical therapy; 955 non-randomized, 430
receiving surgery and 525 medical therapy); for simplicity, we only report analyses restricted
to patients with complete data. Table 4 summarizes baseline covariates in trial participants
(by treatment group) and non-participants. Figure 1 presents the kernel density of the es-
timated probability of trial participation for trial participants and non-participants and a
kernel density of the estimated weights for trial participants. The sample proportion of non-
participants divided by the sample average of the inverse odds of trial participation among
trial participants was approximately 1.001.
Estimates of the 10-year risk (by treatment group), risk difference, and risk ratio are
shown in Table 5. The outcome model-based estimator (OM), the inverse odds of partic-
ipation estimators (IOW1 and IOW2), and the doubly robust estimators (DR1, DR2 and
DR3) produced similar results, suggesting that findings are not driven by model specification
decisions [29].
7 Transportability analyses in practice
We now discuss practical issues related to variable selection, other aspects of model specifi-
cation, and positivity violations and highly variable weights, all of which arise in transporta-
bility analyses using the methods described above.
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7.1 Practical considerations
Variable selection: Throughout, we have used X to signify baseline covariates measured
both among randomized trial participants and the sample from the target population. In
principle, investigators can use any subset of the available covariates that satisfies the mean
transportability assumption. When investigators are interested in estimating the potential
outcome mean under each treatment (not only the average treatment effect), outcome pre-
dictors that are also associated with trial participation should be included in models for the
outcome and the probability of participation (or both, when using doubly robust estimators).
Including outcome predictors that are not associated with trial participation in models for
the expectation of the outcome will often improve the precision of the outcome model-based
and doubly robust estimators; including strong predictors of trial participation that are not
associated with the outcome in regressions for the probability of participation will generally
increase the variance of the odds weighted and doubly robust estimators without improving
transportability. When investigators are primarily interested in the average treatment effect
(instead of the potential outcome mean under each treatment), only effect modifiers (on the
mean difference scale) need to be modeled [8, 12]. Because background knowledge about
effect modification is typically very limited, even when interest is centered on treatment
effect estimation, in practice it is probably best to include as many outcome predictors as
possible in regression models for the expectation of the outcome or the probability of trial
participation. We followed this strategy in our CASS re-analysis: we selected covariates for
“adjustment” based on prior work on outcome modeling and used the same covariates when
modeling trial participation, the outcome, and treatment in the trial.
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Other aspects of model specification: Models for the expectation of the outcome and
the probability of trial participation need to be flexible in order to approximate the corre-
sponding “true” conditional expectation/probability functions. This will often mean includ-
ing non-linear terms (e.g., splines for continuous variables) or interactions between predictors.
When modeling the expectation of the outcome (for outcome model-based or doubly robust
estimators) we recommend fitting separate regression models in each treatment group in the
trial, as we did in the CASS re-analysis (equivalent to fitting a single regression model that
includes all possible treatment-covariate interactions).
More broadly, model specification for transportability analyses involves trading off bias
and variance using informal [46] or formal methods (e.g., [47]). When background knowledge
suggests that a large number of covariates need to be modeled, formal model specification
search methods can be particularly helpful. In our experience, especially when using com-
posite datasets, the variables measured both among trial participants and the sample of the
target population are often few and model specification is not a pressing concern (of course,
such cases raise concerns about violations of the mean transportability assumption and ne-
cessitate sensitivity analyses, which we address in the discussion). When richer data are
available (e.g., when trials are nested in cohorts of eligible individuals [22]), transportabil-
ity analyses need to be combined with more sophisticated strategies for model specification
search (e.g., [48] provides an overview in the context of causal inference for observational
studies, but the same principles apply to transportability analyses).
Positivity violations and highly variable weights: To prevent structural violations
of the positivity of trial participation assumption, investigators should ensure that the sam-
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ple from the target population meets the trial eligibility criteria. For example, if the trial
restricted enrollment to patients under 85 years of age, it is prudent to apply the same
restriction in the sample of patients from the target population. When positivity is vio-
lated, odds weighting estimators are inconsistent, whereas outcome model-based and doubly
robust estimators rely heavily on the specification of the outcome model (to extrapolate
from participants to non-participants) [49]. Empirical (finite-sample) violations of positivity
can arise due to chance, particularly when the trial sample size is small or when the mean
transportability assumption requires adjustment for continuous covariates or a large number
of discrete covariates. Empirical violations of positivity increase bias and variance in a way
that depends on the particular estimator being used, model specification, and the underlying
data generating mechanism.
It is always a good idea to examine the distribution of the estimated probabilities of trial
participation (even if using an outcome model-based estimator), because values near zero are
warning signs for possible positivity violations. Inspection of the estimated probabilities of
trial participation can be combined with diagnostics for positivity violations [49]. It is also
useful to inspect the distribution of the weights that are used for the odds weighting and
doubly robust estimators. By inspecting the distribution of the odds weights, investigators
can identify extreme values and visually assess the spread of the weight distribution. A
sometimes useful diagnostic is that the sample proportion of non-participants divided by the
sample average of the estimated inverse odds of trial participation among trial participants,
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should be approximately equal to one; or, in symbols
n∑
i=1
(1− Si)
n∑
i=1
Si
1− h(Xi; γ̂)
h(Xi; γ̂)
≈ 1.
Values different from 1, suggest positivity violations or model misspecification.1
In applied analyses, we have found that problems with extreme weights can often be
addressed by making sensible modeling choices [46] and ensuring that the sample of non-
participants is properly selected to avoid violations of the positivity of trial participation
assumption. Trimming or truncation of extreme weights may also help, but these strategies
shift the causal estimand, which is often undesirable.
In our CASS re-analyses, the estimated probabilities of trial participation were far from
zero. Their distribution was similar among trial participants and non-participants (as shown
in Figure 1), reflecting the fairly similar observed covariate distribution in trial participants
and non-participants and the absence of strong selection into the trial (at least based on avail-
able covariates, as shown in Table 4). As noted, the sample proportion of non-participants
divided by the sample average of the inverse odds of trial participation among trial partic-
ipants was approximately 1, providing some reassurance that gross violations of positivity
were absent.
1The rationale for the diagnostic is provided by the identity Pr[S = 0] = E
[
S
Pr[S = 0|X]
Pr[S = 1|X]
]
.
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8 Discussion
In this tutorial, we reviewed methods for transporting inferences about the average effect
of a time-fixed treatment from a randomized clinical trial to a new target population using
baseline covariate data from randomized participants and a sample from the target popula-
tion, but treatment and outcome data only from the randomized participants. We considered
estimation approaches that rely on modeling the probability of trial participation, the ex-
pectation of the outcome, or both, and can be implemented easily in all popular statistical
software packages.
A major challenge in applying any of the methods discussed in this tutorial is the need
to collect adequate covariate information, both from trial participants and non-participants,
for the mean transportability assumption to hold. Because the transportability assumption
is not testable using the observed data, one has to rely on background substantive knowledge
to assess its plausibility. Reasoning about the assumption can be facilitated using directed
acyclic graphs, including recent graphical identification algorithms for assessing transporta-
bility [50–52]. Because background knowledge is often incomplete, it is often necessary to
conduct sensitivity analyses, to examine how violations of the transportability assumption
influence study results [53,54].
Methods related to those discussed in this tutorial have been discussed in a number of
recent publications [6–15] addressing trial transportability (or the related but distinct con-
cept of generalizability [55]). With few exceptions – such as the careful asymptotic study of
an estimator closely related to DR1 in [12], or the targeted maximum likelihood estimators
in [14] – prior work has focused on weighting [6,11,15] or stratification-based methods [8–10]
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that only rely on the probability of trial participation. Theoretical arguments, our simulation
results, and practical experience suggest that methods that combine modeling the probabil-
ity of trial participation with modeling the expectation of the outcome are most promising
for applied work for two reasons: first, the double robustness property in effect gives inves-
tigators two opportunities for approximately correct inference [29]; second, doubly robust
estimators often produce estimates that are more precise than those from methods that
exclusively rely on modeling the probability of trial participation, even when the outcome
model is misspecified [26,29,32,56]. In our simulation studies, which used correctly specified
parametric working models with few covariates, all estimators performed reasonably well in
terms of bias. Interestingly, the two inverse odds weighting estimators had very different
finite-sample performance in the presence of strong selection. Based on this observation, we
recommend avoiding weighted estimators that do not normalize the weights to sum to 1.
When data are available on numerous baseline covariates, many of which are continuous,
correct specification of parametric models for the probability of trial participation or expec-
tation of the outcome will be impossible. Future research should address estimation using
more flexible models (e.g., non-parametric or semi-parametric regression) to mitigate model
misspecification. Flexible models are particularly appealing when using doubly robust esti-
mators, because the estimators remain
√
n-consistent even when estimating the conditional
expectation of the outcome or the probability of participation non-parametrically [57, 58].
Further research is also needed to study the behavior of different estimators under misspeci-
fication and to develop alternatives that are more robust to misspecification of the outcome
model (e.g., along the lines suggested in [59, 60]). Lastly, throughout this tutorial, we have
assumed perfect adherence to treatment in the randomized trial, no missing outcome data,
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and no measurement error. In practice, adherence is often imperfect, outcomes are missing
(e.g., due to right censoring in failure-time analyses), and measurement error is a concern
(e.g., differential measurement error in effect modifiers when using composite datasets). Es-
tablished methods to address these issues in the trial data can be combined with the methods
described in this tutorial in a modular fashion. For example, adjustment for imperfect ad-
herence via inverse probability of treatment weighting can be combined with inverse odds
weighting for transportability. Future work should assess the properties of such combined
procedures and evaluate them in practical applications.
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Tables
Table 1: Data structure for binary treatment, A, observed outcome, Y , and baseline co-
variates, X, for trial participants (S = 1) and non-participants (S = 0). The observed
data include (S,X,A, Y ) information from nRCT trial participants, n0 assigned to A = 0 and
n1 assigned to A = 1, and (S,X) information from nobs non-participants, for a total of n
observations. Dashes denote missing data.
Unit S A Y X
1 1 0 y1 x1
... 1
...
...
...
n0 1 0 yn0 xn0
1 + n0 1 1 y1+n0 x1+n0
...
...
...
...
...
n1 + n0 = nRCT 1 1 yn1+n0 xn1+n0
1 + nRCT 0 − − xn1+n0+1
...
...
...
...
...
nobs + nRCT = n 0 − − xn
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Table 2: Selected results from the simulation study: bias of estimators across and sample
sizes, under strong selection on the effect modifier (µ = 1) and strong effect modification
(φ = 1).
nRCT nobs Trial OM IOW1 IOW2 DR1 DR2 DR3
250 2500 0.998 0.002 0.008 0.081 -0.001 0.001 0.002
250 5000 1.003 -0.002 -0.007 0.068 -0.006 -0.007 -0.008
250 10000 0.999 0.005 0.000 0.078 -0.001 0.002 0.003
500 2500 1.000 0.000 0.022 0.067 0.001 -0.000 0.000
500 5000 1.003 -0.000 -0.004 0.054 -0.003 -0.002 -0.001
500 10000 1.000 -0.001 -0.013 0.045 -0.004 -0.003 -0.003
1000 2500 1.000 -0.001 0.010 0.031 -0.001 0.001 0.002
1000 5000 1.000 -0.001 -0.005 0.021 -0.004 -0.004 -0.005
1000 10000 1.000 -0.000 -0.011 0.014 -0.005 -0.003 -0.003
Trial = trial-only, unadjusted estimator; OM = outcome modeling followed by marginaliza-
tion; IOW1 = estimator (2); IOW2 = estimator (3); DR1 = estimator (4); DR2 = estimator
(5); DR3 = estimator (6). Additional simulation results are presented in the Appendix.
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Table 3: Selected results from the simulation study: variance of estimators across and sample
sizes, under strong selection on the effect modifier (µ = 1) and strong effect modification
(φ = 1).
nRCT nobs Trial OM IOW1 IOW2 DR1 DR2 DR3
250 2500 0.087 0.067 4.698 1.341 0.300 0.164 0.172
250 5000 0.089 0.068 5.324 1.387 0.342 0.166 0.176
250 10000 0.090 0.066 3.295 1.399 0.291 0.163 0.173
500 2500 0.044 0.034 2.515 0.962 0.169 0.100 0.095
500 5000 0.043 0.033 2.016 0.962 0.143 0.096 0.092
500 10000 0.044 0.032 2.321 0.945 0.161 0.096 0.093
1000 2500 0.022 0.016 1.094 0.617 0.087 0.055 0.049
1000 5000 0.023 0.016 1.070 0.644 0.088 0.057 0.050
1000 10000 0.022 0.016 1.088 0.667 0.081 0.056 0.049
Trial = trial-only, unadjusted estimator; OM = outcome modeling followed by marginaliza-
tion; IOW1 = estimator (2); IOW2 = estimator (3); DR1 = estimator (4); DR2 = estimator
(5); DR3 = estimator (6). Additional simulation results are presented in the Appendix.
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Table 4: Baseline covariates in the CASS (August 1, 1975 to Dec 31, 1989).
Variable Level
Non
participants
Trial participants
Surgery Medical
N 955 368 363
Age, years 50.9 (7.7) 51.4 (7.2) 50.9 (7.4)
Angina None 195 (20.4) 83 (22.6) 81 (22.3)
Present 760 (79.6) 285 (77.4) 282 (77.7)
History of MI No 406 (42.5) 159 (43.2) 135 (37.2)
Yes 549 (57.5) 209 (56.8) 228 (62.8)
LAD % obstruction 39.1 (38.7) 36.4 (38.0) 34.9 (37.0)
Left ventricular score 7.1 (2.7) 7.4 (2.9) 7.3 (2.8)
Diseased vessels 0 347 (36.3) 146 (39.7) 133 (36.6)
≥ 1 608 (63.7) 222 (60.3) 230 (63.4)
Ejection fraction, % 60.2 (12.3) 60.9 (13.1) 59.8 (12.8)
Results presented as mean (SD) for continuous variables and count (%) for discrete variables.
CASS = Coronary Artery Surgery Study; LAD = left anterior descending coronary artery;
MI = myocardial infarction; SD = standard deviation.
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Figure
Figure 1: Kernel densities for the estimated probability of trial participation for trial partici-
pants (left panel, solid line) and non-participants (left panel, dashed line), and the estimated
weights for trial participants (right panel). The weights for trial participants are equal to
the inverse of the estimated odds of trial participation times the inverse of the estimated
probability of receiving the treatment actually received, as defined in Section 4.2.
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Appendix
In this Appendix we collect results regarding the consistency and double robustness proper-
ties of estimators discussed in the tutorial.
Identification
Under the assumptions in Section 3, the potential outcome mean among non-participants
can be identified by the observed data:
E[Y a|S = 0] = E[E[Y a|X,S = 0]|S = 0]
= E
[
E[Y a|X,S = 1]|S = 0]
= E
[
E[Y a|X,A = a, S = 1]|S = 0]
= E
[
E[Y |X,A = a, S = 1]|S = 0].
Consistency and double robustness
In what follows, we assume that the model for the probability of treatment among trial
participants is correctly specified (in fact, the “true” probability can be used instead).
OM: When the model for the expectation of the outcome is correctly specified,
ga(X; β̂)
p→ ga(X; β) = E[Y |X,A = a, S = 1], so that µ̂OM(a) p→
E
[
E[Y |X,A = a, S = 1](1− S)]
Pr[S = 0]
.
Consistency of µ̂OM(a) follows because the numerator of the last expression above can be
re-written as
E
[
E[Y |X,A = a, S = 1](1− S)] = E[E[Y |X,A = a, S = 1]|S = 0]Pr[S = 0]
= E[Y a|S = 0] Pr[S = 0],
where the last equality follows from the identification result above.
IOW1: When the model for the probability of trial participation is correctly specified,
h(X; γ̂)
p→ h(X; γ) = Pr[S = 1|X], ea(X; θ̂) p→ ea(X; θ) = Pr[A = a|X,S = 1], so that
µ̂IOW1(a)
p→
E
[
Pr[S = 0|X]SI(A = a)Y
Pr[S = 1|X] Pr[A = a|X,S = 1]
]
Pr[S = 0]
.
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Consistency of µ̂IOW1(a) follows because the numerator of the last expression above can be
re-written as
E
[
Pr[S = 0|X]SI(A = a)Y
Pr[S = 1|X] Pr[A = a|X,S = 1]
]
= E
[
Pr[S = 0|X]E[SI(A = a)Y |X]
Pr[S = 1|X] Pr[A = a|X,S = 1]
]
= E
[
Pr[S = 0|X]E[Y |X,A = a, S = 1]]
= E
[
Pr[S = 0|X]E[Y a|X,S = 0]]
= E
[
E[Y a(1− S)|X]]
= E[Y a|S = 0] Pr[S = 0].
IOW2: When the model for the probability of trial participation is correctly specified,
IOW2 converges to the same limit as IOW1 because
E
[(
1− h(X; γ))SI(A = a)
h(X; γ)ea(X; γ)
]
= E
[
Pr[S = 0|X]E[SI(A = a)|X]
Pr[S = 1|X] Pr[A = a|X,S = 1]
]
= Pr[S = 0]. (A.1)
Influence function for the observed data functional: Write the observed data func-
tional as χp(a) = Ep[Ep[Y |X,A = a, S = 1]|S = 0], where p is the observed data law. The
first order influence function for χp(a) is
χ1p0(a) =
1
Prp0 [S = 0]
{
SI(A = a)
Prp0 [S = 0|X]
Prp0 [S = 1, A = a|X]
{
Y − Ep0 [Y |X,A = a, S = 1]
}
+ (1− S)
{
Ep0 [Y |X,A = a, S = 1]− χp0(a)
}}
,
where the 0 subscript indicates the “true” law. The above influence function implies the
following in-sample one-step estimator for χp(a):
χ̂(a) =
1
nP̂r[S = 0]
n∑
i=1
{
SiI(Ai = a)
1− ĥ(Xi)
ĥ(Xi)êa(Xi)
{
Yi − ĝa(Xi)
}
+ (1− Si)ĝa(Xi)
}
,
where P̂r[S = 0] is the estimated proportion of non-participants, and ĥ(X), êa(X), and ĝa(X)
are generic estimators for Pr[S = 1|X], Pr[A = a|X,S = 1], and E[Y |X,A = a, S = 1], re-
spectively. Of note, this result suggests that, unless one is willing to make assumptions
beyond those in Section 3, estimators of E[Y a|S = 0] should ignore treatment and outcome
data in the sample of trial-eligible non-participants from the target population (i.e., indi-
viduals with S = 0), even if available (see [12] for a similar observation). Estimator DR1
in the main text of the tutorial is obtained from χ̂(a), using parametric models to estimate
conditional probabilities and expectations.
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Double robustness of DR1: Provided the limiting values for the working models exist
(even if the models are misspecified), DR1 converges to
µ̂DR1(a)
p→ 1
Pr[S = 0]
{
E
[
1− h(X; γ)
h(X; γ)ea(X; θ)
SI(A = a)Y
]
− E
[
1− h(X; γ)
h(X; γ)ea(X; θ)
SI(A = a)ga(X; β)
]
+ E
[
(1− S)ga(X; β)
]}
.
(A.2)
We now consider two cases with respect to potential misspecification of the working
models for the probability of treatment and the expectation of the outcome.
h(X; γ) correctly specified; ga(X; β) incorrectly specified: following the argument
for estimator IOW1, the first term in the bracketed part of (A.2) converges to E[Y a|S =
0] Pr[S = 0]; by iterated expectation, the sum of the other two terms converges to 0.
ga(X; β) correctly specified; h(X; γ) incorrectly specified: following the argument for
the OM estimator, the last term in the bracketed part of (A.2) converges to E[Y a|S =
0] Pr[S = 0]; by iterated expectation, the sum of the other two terms converges to 0.
DR2: When the model for the probability of trial participation is correctly specified, DR2
converges to the same limit as DR1 because of (A.1). When the model for the expectation
of the outcome is correctly specified, DR2 converges to the same limit as DR1 because, by
iterated expectation, the first term of the estimator in equation (5) of the main text converges
to 0.
Double robustness of DR3: The consistency and double robustness properties of the
weighted regression based estimator follows from properties of quasi-likelihood estimation in
linear exponential families [30] and standard weighted optimization arguments [31].
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Complete simulation results
Table A1: Bias of estimators across different magnitudes of effect modification (φ), selection
effects (µ), and sample sizes.
nRCT nobs φ µ Trial OM IOW1 IOW2 DR1 DR2 DR3
250 2500 0 0 -0.001 -0.000 0.009 0.011 0.002 0.002 0.003
250 2500 0 1 -0.002 -0.003 0.010 -0.004 -0.001 -0.001 -0.000
250 2500 1 0 -0.007 -0.001 0.020 0.009 -0.003 -0.002 -0.002
250 2500 1 1 0.998 0.002 0.008 0.081 -0.001 0.001 0.002
250 5000 0 0 -0.003 -0.000 0.011 0.005 -0.001 -0.000 0.001
250 5000 0 1 0.000 0.003 -0.023 0.001 0.012 0.008 0.005
250 5000 1 0 -0.001 -0.001 -0.005 -0.004 0.003 0.003 0.004
250 5000 1 1 1.003 -0.002 -0.007 0.068 -0.006 -0.007 -0.008
250 10000 0 0 -0.000 0.002 -0.005 -0.004 0.000 0.002 0.002
250 10000 0 1 -0.002 -0.001 -0.019 -0.003 -0.004 -0.005 -0.003
250 10000 1 0 0.005 0.004 -0.007 -0.002 0.002 0.002 0.002
250 10000 1 1 0.999 0.005 0.000 0.078 -0.001 0.002 0.003
500 2500 0 0 0.000 -0.000 0.010 0.008 -0.000 0.001 0.001
500 2500 0 1 0.003 0.002 -0.008 -0.001 0.001 0.003 0.003
500 2500 1 0 -0.002 -0.001 -0.005 -0.003 -0.001 -0.001 -0.001
500 2500 1 1 1.000 0.000 0.022 0.067 0.001 -0.000 0.000
500 5000 0 0 0.001 0.000 0.005 0.006 -0.002 -0.002 -0.001
500 5000 0 1 0.001 -0.001 -0.012 -0.005 -0.007 -0.005 -0.003
500 5000 1 0 -0.000 0.003 0.006 0.004 0.002 0.002 0.002
500 5000 1 1 1.003 -0.000 -0.004 0.054 -0.003 -0.002 -0.001
500 10000 0 0 0.001 -0.001 -0.001 0.001 -0.001 -0.001 -0.001
500 10000 0 1 -0.003 -0.001 -0.001 0.002 0.001 0.000 0.000
500 10000 1 0 0.002 -0.001 -0.016 -0.013 -0.002 -0.002 -0.002
500 10000 1 1 1.000 -0.001 -0.013 0.045 -0.004 -0.003 -0.003
1000 2500 0 0 0.001 -0.001 0.003 0.001 0.001 0.000 -0.000
1000 2500 0 1 -0.001 -0.001 -0.014 -0.003 -0.000 -0.001 -0.002
1000 2500 1 0 -0.000 -0.001 -0.004 -0.002 -0.001 -0.001 -0.001
1000 2500 1 1 1.000 -0.001 0.010 0.031 -0.001 0.001 0.002
1000 5000 0 0 0.000 0.001 -0.000 -0.000 -0.000 -0.000 -0.000
1000 5000 0 1 -0.001 -0.003 0.005 0.006 -0.000 -0.001 -0.002
1000 5000 1 0 -0.001 -0.002 -0.001 -0.002 -0.002 -0.002 -0.003
1000 5000 1 1 1.000 -0.001 -0.005 0.021 -0.004 -0.004 -0.005
1000 10000 0 0 -0.001 0.001 -0.003 -0.002 0.002 0.002 0.002
1000 10000 0 1 -0.000 -0.001 0.013 0.010 0.004 0.003 0.002
1000 10000 1 0 0.000 -0.000 0.004 0.002 -0.003 -0.003 -0.002
1000 10000 1 1 1.000 -0.000 -0.011 0.014 -0.005 -0.003 -0.003
Trial = trial-only, unadjusted estimator; OM = outcome modeling followed by marginaliza-
tion; IOW1 = estimator (2); IOW2 = estimator (3); DR1 = estimator (4); DR2 = estimator
(5); DR3 = estimator (6).
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Table A2: Variance of estimators across different magnitudes of effect modification (φ),
selection effects (µ), and sample sizes.
nRCT nobs φ µ Trial OM IOW1 IOW2 DR1 DR2 DR3
250 2500 0 0 0.066 0.050 0.691 0.504 0.114 0.094 0.093
250 2500 0 1 0.063 0.067 4.032 0.999 0.328 0.164 0.177
250 2500 1 0 0.088 0.051 1.303 0.629 0.125 0.097 0.094
250 2500 1 1 0.087 0.067 4.698 1.341 0.300 0.164 0.172
250 5000 0 0 0.064 0.050 1.009 0.508 0.115 0.094 0.094
250 5000 0 1 0.063 0.067 2.760 0.961 0.276 0.164 0.174
250 5000 1 0 0.090 0.050 0.952 0.637 0.122 0.096 0.094
250 5000 1 1 0.089 0.068 5.324 1.387 0.342 0.166 0.176
250 10000 0 0 0.067 0.051 0.902 0.513 0.123 0.097 0.095
250 10000 0 1 0.063 0.067 2.897 0.988 0.298 0.162 0.174
250 10000 1 0 0.086 0.050 0.854 0.629 0.111 0.091 0.092
250 10000 1 1 0.090 0.066 3.295 1.399 0.291 0.163 0.173
500 2500 0 0 0.032 0.024 0.435 0.319 0.061 0.051 0.047
500 2500 0 1 0.032 0.034 1.572 0.712 0.169 0.098 0.092
500 2500 1 0 0.044 0.025 0.437 0.369 0.062 0.052 0.049
500 2500 1 1 0.044 0.034 2.515 0.962 0.169 0.100 0.095
500 5000 0 0 0.032 0.024 0.389 0.311 0.059 0.050 0.046
500 5000 0 1 0.032 0.033 1.443 0.699 0.157 0.098 0.094
500 5000 1 0 0.044 0.024 0.450 0.363 0.059 0.051 0.047
500 5000 1 1 0.043 0.033 2.016 0.962 0.143 0.096 0.092
500 10000 0 0 0.032 0.025 0.372 0.311 0.057 0.050 0.047
500 10000 0 1 0.032 0.033 1.431 0.700 0.150 0.099 0.093
500 10000 1 0 0.045 0.024 0.509 0.367 0.060 0.051 0.048
500 10000 1 1 0.044 0.032 2.321 0.945 0.161 0.096 0.093
1000 2500 0 0 0.016 0.012 0.182 0.176 0.030 0.027 0.025
1000 2500 0 1 0.016 0.016 1.134 0.457 0.077 0.055 0.049
1000 2500 1 0 0.021 0.013 0.227 0.211 0.030 0.028 0.025
1000 2500 1 1 0.022 0.016 1.094 0.617 0.087 0.055 0.049
1000 5000 0 0 0.016 0.012 0.174 0.173 0.029 0.027 0.025
1000 5000 0 1 0.016 0.016 0.658 0.451 0.075 0.056 0.049
1000 5000 1 0 0.022 0.013 0.240 0.219 0.031 0.028 0.025
1000 5000 1 1 0.023 0.016 1.070 0.644 0.088 0.057 0.050
1000 10000 0 0 0.016 0.012 0.170 0.176 0.030 0.027 0.025
1000 10000 0 1 0.016 0.016 0.798 0.462 0.077 0.057 0.050
1000 10000 1 0 0.022 0.012 0.222 0.211 0.030 0.027 0.025
1000 10000 1 1 0.022 0.016 1.088 0.667 0.081 0.056 0.049
Trial = trial-only, unadjusted estimator; OM = outcome modeling followed by marginaliza-
tion; IOW1 = estimator (2); IOW2 = estimator (3); DR1 = estimator (4); DR2 = estimator
(5); DR3 = estimator (6).
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